StreetAlpha
13F holdings · Q3 2026

Rhenman & Partners Asset Management AB

Stockholm, V7 · files as Rhenman & Partners Asset Management AB
Know the moment Rhenman & Partners Asset Management AB filesYou follow Rhenman & Partners Asset Management AB An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 12, 2026Next filing due Feb 15, 2027CIK 1599882

Rhenman & Partners Asset Management AB reported 93 stocks worth $903M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are IOVA (4.1%), AZN (3.4%) and MRK (3.3%). Compared with Q2 2026, the fund opened new positions in UTHR, VERA and CYTK, added to IOVA, AZN and MDT, trimmed MRK, UNH and GILD and sold out of NTRA, ELV and MLYS.

Latest filing: what Rhenman & Partners Asset Management AB did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
15 new27 added49 trimmed21 sold outBought about $155M · sold about $308M
New 15
See all 15 →
Added 27
See all 27 →
Trimmed 49
  • SYK−$17.6M−98%
  • GKOS−$15.9M−82%
  • TMO−$10.8M−51%
  • ABBV−$9.2M−36%
  • THC−$8.3M−38%
See all 49 →
Sold out 21
See all 21 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$903M−14.8% vs last quarter
Stocks held9315 new · 21 sold out
Top 5 weight16.9%spread out
Turnover51%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
IOVA
Iovance Biotherapeutics Inc
$37.1M4.1%2.5M+797K (+47%)8 of 8
2
AZN
Astrazeneca PLC Ord
$30.3M3.4%185K+34K (+22%)2 of 8
3
MRK
Merck & Co Inc
$30.1M3.3%207K−6,600 (−3%)4 of 8
4
MDT
Medtronic PLC F
$29.3M3.3%340K+195K (+134%)8 of 8
5
UNH
Unitedhealth Group Inc
$26.2M2.9%71K−22K (−24%)8 of 8
6
VRTX
Vertex Pharmaceuticals I
$25.6M2.8%49K+18K (+59%)8 of 8
7
GILD
Gilead Sciences Inc
$23.7M2.6%159K−19K (−11%)8 of 8
8
EW
Edwards Lifesciences Cor
$23.6M2.6%273K+13K (+5%)6 of 8
9
BMRN
Biomarin Pharmaceutical Inc
$23.2M2.6%387K+96K (+33%)8 of 8
10
BIIB
Biogen Inc
$21.9M2.4%97K+2,200 (+2%)8 of 8
🔒 83 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
NTRA
Natera Inc
$16.6M61K
ELV
Elevance Health Inc
$13.5M35K
MLYS
Mineralys Therapeutics Inc
$11.2M416K
ALGN
Align Technology Inc
$10.6M63K
MLTX
Moonlake Immunotherapeutics
$7.5M385K

🔒 Free account: see all 21.

Reported value

last 8 quarters
$973MQ4 '24
$870MQ1 '25
$791MQ2 '25
$904MQ3 '25
$1.1BQ4 '25
$810MQ1 '26
$1.1BQ2 '26
$903MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 12, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Rhenman & Partners Asset Management AB 13F FAQ

What does Rhenman & Partners Asset Management AB own?

Rhenman & Partners Asset Management AB reported 93 stocks worth $903M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are IOVA (4.1%), AZN (3.4%) and MRK (3.3%). The table above lists every position in the filing (the top 10 without an account).

What did Rhenman & Partners Asset Management AB buy and sell in Q3 2026?

Compared with Q2 2026: 15 new positions, 27 added to, 49 trimmed and 21 sold out. New positions include UTHR, VERA and CYTK. It sold all of NTRA, ELV and MLYS.

When will Rhenman & Partners Asset Management AB file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Rhenman & Partners Asset Management AB's portfolio worth?

The Q3 2026 filing reports $903M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.